Tocagen Inc (NASDAQ:TOCA) has received a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.

Brokers have set a 12 month consensus price target of $23.67 for the company, according to Zacks. Zacks has also given Tocagen an industry rank of 93 out of 265 based on the ratings given to its competitors.

Several analysts recently issued reports on the company. Stifel Nicolaus reiterated a “buy” rating and set a $24.00 target price on shares of Tocagen in a report on Tuesday, July 25th. Zacks Investment Research upgraded Tocagen from a “sell” rating to a “hold” rating in a report on Thursday.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund bought a new stake in Tocagen during the second quarter worth about $108,000. TD Asset Management Inc. bought a new stake in Tocagen in the second quarter valued at approximately $158,000. Schwab Charles Investment Management Inc. bought a new stake in Tocagen in the second quarter valued at approximately $165,000. California State Teachers Retirement System bought a new stake in Tocagen in the second quarter valued at approximately $179,000. Finally, Teachers Advisors LLC bought a new stake in Tocagen in the second quarter valued at approximately $181,000. Institutional investors and hedge funds own 37.87% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/18/tocagen-inc-toca-receives-consensus-rating-of-buy-from-brokerages.html.

Tocagen (NASDAQ:TOCA) traded up 3.32% during midday trading on Monday, hitting $13.06. The stock had a trading volume of 144,128 shares. The firm’s market cap is $258.71 million. Tocagen has a 52 week low of $9.68 and a 52 week high of $17.95. The stock has a 50-day moving average of $12.27 and a 200-day moving average of $13.40.

Tocagen (NASDAQ:TOCA) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.04). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. Analysts forecast that Tocagen will post ($2.51) EPS for the current fiscal year.

About Tocagen

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Get a free copy of the Zacks research report on Tocagen (TOCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related stocks with our FREE daily email newsletter.